{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:15:58Z","timestamp":1753892158232,"version":"3.41.2"},"reference-count":74,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Drug package inserts are a crucial foundation for clinical medication practices and serve as the legal basis for guiding rational drug use and ensuring patient safety and efficacy. As rare disease treatments evolve, current package inserts often need to meet the clinical requirements for treating such conditions, frequently resulting in off-label drug use. This consensus is derived from discussions between Guangdong Pharmaceutical Association Hematologic Rare Diseases Group experts. The consensus aims to provide a framework and reference for the clinical application of off-label drug use in treating rare hematologic diseases.<\/jats:p>","DOI":"10.3389\/fphar.2024.1477550","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T09:12:23Z","timestamp":1732266743000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Expert consensus on the off-label use in China of drugs for rare hematologic diseases (2024 edition)"],"prefix":"10.3389","volume":"15","author":[{"given":"Boxin","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisheng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liya","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfen","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuqin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingtong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianlong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maobai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiran","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taotao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhichang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Guangdong Pharmaceutical Association, Hematology Group of Rare Disease Expert Committee of Guangdong Pharmaceutical Association","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1056\/NEJM200107193450318","article-title":"Pamidronate for bone pain from osteolytic lesions in Langerhans'-cell histiocytosis","volume":"345","author":"Arzoo","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/(sici)1096-911x(199701)28:1<9::aid-mpo3>3.0.co;2-p","article-title":"Langerhans'-cell histiocytosis in adults","volume":"28","author":"Baumgartner","year":"1997","journal-title":"Med. Pediatr. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/DMA-2010-0735","article-title":"The Wiskott-Aldrich syndrome: the actin cytoskeleton and immune cell function","volume":"29","author":"Blundell","year":"2010","journal-title":"Dis. Markers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria","volume":"124","author":"Brodsky","year":"2014","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/ejh.12492","article-title":"Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome","volume":"95","author":"Cai","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.tig.2017.11.006","article-title":"Multifaceted Fanconi anemia signaling","volume":"34","author":"Che","year":"2018","journal-title":"Trends Genet."},{"key":"B7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.7326\/M16-1565","article-title":"A reporting tool for practice guidelines in Health care: the RIGHT statement","volume":"166","author":"Chen","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3760\/cma.j.cn112137-20200219-00349","article-title":"Expert consensus on the diagnosis and treatment of porphyria in China","volume":"100","year":"2020","journal-title":"Chin. Med. J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3760\/cma.j.cn112138-20220106-00014","article-title":"Research progress in the treatment of adult Langerhans cell histiocytosis","volume":"62","author":"Dai","year":"2023","journal-title":"Chin. J. Intern. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/pbc.21225","article-title":"Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine","volume":"50","author":"Dhall","year":"2008","journal-title":"Pediatr. Blood Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood-2014-03-561381","article-title":"Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease","volume":"124","author":"Diamond","year":"2014","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/ajh.26240","article-title":"POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management","volume":"96","author":"Dispenzieri","year":"2021","journal-title":"Am. J. Hematol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/00043426-200101000-00013","article-title":"Treatment of Langerhans cell histiocytosis with pamidronate","volume":"23","author":"Farran","year":"2001","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1038\/s41375-018-0209-7","article-title":"European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias","volume":"32","author":"Gavriatopoulou","year":"2018","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2014-09-602573","article-title":"Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome\/X-linked thrombocytopenia","volume":"126","author":"Gerrits","year":"2015","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1182\/blood-2015-01-620377","article-title":"Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial","volume":"126","author":"Gianfreda","year":"2015","journal-title":"Blood"},{"key":"B17","unstructured":"Notice on the release of the Off-Label drug use catalog2023"},{"key":"B18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jaci.2006.02.005","article-title":"The Wiskott-Aldrich syndrome","volume":"117","author":"Hans","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1182\/blood.2019002766","article-title":"Erdheim-Chester disease","volume":"135","author":"Haroche","year":"2020","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/bjh.14497","article-title":"Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen","volume":"181","author":"He","year":"2018","journal-title":"Br. J. Haematol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3760\/cma.j.issn.0253-2727.2021.07.001","article-title":"The consensus of the diagnosis and treatment of Castleman disease in China (2021)","volume":"42","year":"2021","journal-title":"Chin. J. Hematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3760\/cma.j.issn.0253-2727.2016.09.003","article-title":"The consensus of the diagnosis and treatment of primary light chain amyloidosis in China (2016 version)","volume":"37","year":"2016","journal-title":"Chin. J. Hematol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJM200111223452118","article-title":"Successful treatment of Langerhans'-cell histiocytosis with etanercept","volume":"345","author":"Henter","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1136\/adc.82.6.483","article-title":"Long term follow up of topical mustine treatment for cutaneous Langerhans cell histiocytosis","volume":"82","author":"Hoeger","year":"2000","journal-title":"Arch. Dis. Child."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1741-7015-12-2","article-title":"Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial","volume":"12","author":"Huang","year":"2014","journal-title":"BMC Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/00000421-199212000-00011","article-title":"Treatment of Langerhans cell histiocytosis in children with etoposide","volume":"15","author":"Ishii","year":"1992","journal-title":"Am. J. Clin. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1182\/blood.v57.4.692.692","article-title":"Reconstitution of normal megakaryocytopoiesis and immunologic functions in Wiskott-Aldrich syndrome by marrow transplantation following myeloablation and immunosuppression with busulfan and cyclophosphamide","volume":"57","author":"Kapoor","year":"1981","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s002770050236","article-title":"Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multi-center trial","volume":"73","author":"Kersten","year":"1996","journal-title":"Ann. Hematol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/jamaoncol.2021.0586","article-title":"Update on the diagnosis and treatment of POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome: a review","volume":"7","author":"Khouri","year":"2021","journal-title":"JAMA Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1182\/blood.2019003633","article-title":"Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria","volume":"135","author":"Kimmich","year":"2020","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3109\/08880019709028774","article-title":"Treatment of relapsed Langerhans cell histiocytosis by cyclosporin A combined with etoposide and prednisone","volume":"14","author":"Korholz","year":"1997","journal-title":"Pediatr. Hematol. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jocn.2010.07.124","article-title":"Clinicopathological profile of polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes (POEMS) syndrome","volume":"18","author":"Kulkarni","year":"2011","journal-title":"J. Clin. Neurosci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1182\/blood.v79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989 [see comments]","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00277-010-1149-0","article-title":"Clinical characteristics and long-term outcome of patients with POEMS syndrome in China","volume":"90","author":"Li","year":"2011","journal-title":"Ann. Hematol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1182\/blood.v77.4.721.bloodjournal774721","article-title":"Cyclosporine therapy for advanced Langerhans cell histiocytosis [see comments]","volume":"77","author":"Mahmoud","year":"1991","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/nyas.12049","article-title":"Wiskott-Aldrich syndrome: a comprehensive review","volume":"1285","author":"Massaad","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"37","DOI":"10.25259\/JCIS_68_2020","article-title":"Erdheim-Chester disease: a case report and review of the literature","volume":"10","author":"Merai","year":"2020","journal-title":"J. Clin. Imaging Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S1474-4422(16)30157-0","article-title":"Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"15","author":"Misawa","year":"2016","journal-title":"Lancet Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1182\/blood.v87.7.3063.bloodjournal8773063","article-title":"High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement [letter]","volume":"87","author":"Moreau","year":"1996","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1182\/blood-2016-09-740217","article-title":"Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations","volume":"129","author":"Nordmann","year":"2017","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/bjh.14966","article-title":"Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial","volume":"179","author":"Nozza","year":"2017","journal-title":"Br. J. Haematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00277-011-1244-x","article-title":"Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide","volume":"91","author":"Palladini","year":"2012","journal-title":"Ann. Hematol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2012.073593","article-title":"A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis","volume":"98","author":"Palladini","year":"2013","journal-title":"Haematologica"},{"key":"B46","doi-asserted-by":"publisher","first-page":"S28-S36","DOI":"10.1016\/j.annemergmed.2020.08.009","article-title":"Trends in sickle cell disease-related mortality in the United States, 1979 to 2017","volume":"76","author":"Payne","year":"2020","journal-title":"Ann. Emerg. Med."},{"key":"B47","unstructured":"The national People\u2019s congress of the People\u2019s Republic of China2021"},{"year":"2021","key":"B48"},{"journal-title":"Pfizer Labs (per FDA). N. Y","article-title":"Immune globulin subcutaneous (human)-hipp subcutaneous solution","year":"2021","key":"B49"},{"volume-title":"Tranexamic acid intravenous injection","year":"2020","key":"B50"},{"volume-title":"Hydroxyurea oral capsules","year":"2015","key":"B51"},{"volume-title":"L-glutamine oral powder","year":"2017","key":"B52"},{"volume-title":"APP pharmaceuticals","year":"2008","key":"B53"},{"year":"2017","key":"B54"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1111\/jth.14217","article-title":"Thrombopoietin receptor agonists in hereditary thrombocytopenias","volume":"16","author":"Rodeghiero","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"B57","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ajh.10053","article-title":"Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine","volume":"69","author":"Rodriguez-Galindo","year":"2002","journal-title":"Am. J. Hematol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1182\/blood.2019004369","article-title":"A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis","volume":"135","author":"Roussel","year":"2020","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3816\/clm.2003.n.005","article-title":"Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis","volume":"3","author":"Seldin","year":"2003","journal-title":"Clin. Lymphoma"},{"key":"B60","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/0002-9343(94)90350-6","article-title":"POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS syndrome","volume":"97","author":"Soubrier","year":"1994","journal-title":"Am. J. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/pbc.20053","article-title":"Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis","volume":"43","author":"Stine","year":"2004","journal-title":"Pediatr. Blood Cancer"},{"year":"2021","key":"B62","article-title":"The specification of evidence-base pharmaceutical evaluation method for off-label drug use"},{"key":"B63","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1182\/bloodadvances.2020003334","article-title":"International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease","volume":"4","author":"van Rhee","year":"2020","journal-title":"Blood Adv."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"32","author":"van Rhee","year":"2018","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ajh.20183","article-title":"Androgens and liver tumors: fanconi's anemia and non-Fanconi's conditions","volume":"77","author":"Velazquez","year":"2004","journal-title":"Am. J. Hematol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/mpo.2950190414","article-title":"Etoposide in the treatment of six children with Langerhans cell histiocytosis (histiocytosis X)","volume":"19","author":"Viana","year":"1991","journal-title":"Med. Ped Oncol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1038\/s41375-022-01555-8","article-title":"Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent\/refractory adult Langerhans cell histiocytosis","volume":"36","author":"Wang","year":"2022","journal-title":"Leukemia"},{"key":"B68","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/imj.12566","article-title":"Management of systemic AL amyloidosis: recommendations of the myeloma foundation of Australia medical and scientific advisory group","volume":"45","author":"Weber","year":"2015","journal-title":"Intern Med. J."},{"key":"B69","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/bjh.13155","article-title":"Guidelines on the management of AL amyloidosis","volume":"168","author":"Wechalekar","year":"2015","journal-title":"Br. J. Haematol."},{"volume-title":"WHO Handbook for guideline development","year":"2014","key":"B70"},{"key":"B71","doi-asserted-by":"publisher","first-page":"89","DOI":"10.16150\/j.1671-2870.2023.02.001","article-title":"Report on diagnosis and treatment of hemophilia in China 2023","volume":"22","author":"Xue","year":"2023","journal-title":"J. Diagn. Concepts Pract."},{"key":"B72","doi-asserted-by":"publisher","first-page":"370\u2013374","DOI":"10.12376\/j.issn.2097-0501.2022.04.002","article-title":"Establishment and evolution of China national hemophilia registry","volume":"1","author":"Xue","year":"2022","journal-title":"J. Rare Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/1096-911x(20001001)35:4<438::aid-mpo12>3.0.co;2-4","article-title":"Multisystem Langerhans-cell histiocytosis with life-threatening pulmonary involvement--good response to cyclosporine A","volume":"35","author":"Zeller","year":"2000","journal-title":"Med. Pediatr. Oncol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"100720","DOI":"10.1016\/j.lanwpc.2023.100720","article-title":"A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria","volume":"34","author":"Zhang","year":"2023","journal-title":"Lancet Reg. Health West Pac"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1477550\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T09:12:39Z","timestamp":1732266759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1477550\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":74,"alternative-id":["10.3389\/fphar.2024.1477550"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1477550","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2024,11,22]]},"article-number":"1477550"}}